content_image/17551.jpg content_image/17553.jpg
## SALES OVERVIEW 

## 2001 Sales  by Product Line* 

Having completed the divestiture of non-strategic businesses in 2001, Edwards has a solid platform from which to grow . 

(A) Cardiac Surgery 

52% 

(B) Critical Care 

33% 

(C) Vascular 

8% 

(D) Perfusion & Other 

7% 

* Sales exclude the impact of divested operations. 

A 

D 

B 

C 

## 2001 Sales  by Region* 

With its extensive global presence, Edwards provides life-saving products to patients in more than 80  countries around the world . 

* End customer sales, excluding the impact of divested operations. 

A 

B 

D 

C 

## UNAUDITED PRO FORMA CONSOLIDATED STATEMENTS OF OPERATIONS 

The following pro forma data are provided for informational purposes and do not represent the historical results of Edwards Lifesciences as reported in the Company’s filings with the Securities and Exchange Commission. 

The following table sets forth the consolidated statements of operations, excluding non-recurring items in 2001 and 2000 , with respect to Edwards Lifesciences (see Note 3 to the “Consolidated Financial Statements”). The non-recurring items in 2001 consist primarily of charges related to the perfusion services divestiture, the impairment of intangible and other assets, and the termination of an interest rate swap contract. The non-recurring items in 2000 consist primarily of charges and severance costs related to the perfusion products divestiture, and the write-down of certain goodwill and other intangible assets. Partially offsetting the charge in 2000 was a gain from the Novacor divestiture. 

This table should be read in conjunction with Edwards Lifesciences’“Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Consolidated Financial Statements” found elsewhere in this Annual Report to Shareholders. Results prior to April 1 , 2000 are pro forma as Edwards Lifesciences was part of Baxter International Inc. through the close of business on March 31 , 2000 . See Note 3 to the “Consolidated Financial Statements” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for further discussions of the effects of certain asset divestitures on Edwards Lifesciences’ operations. 

<img src='content_image/17551.jpg'>

## Operating Statistics 

<img src='content_image/17553.jpg'>

Note: Operating statistics may not foot due to rounding. 

(a) Historical amounts through March 31 , 2000 are pro forma and have been adjusted to reflect: 

GLYPH<squareblack> The Japan operations on the equity method of accounting. 

GLYPH<squareblack> Estimated incremental costs associated with being an independent public company. 

GLYPH<squareblack> The estimated interest expense associated with the Company’s future debt facilities. 

